Literature DB >> 24169803

Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining.

Sara Ares-Santos1, Noelia Granado2, Isabel Espadas1, Ricardo Martinez-Murillo3, Rosario Moratalla1.   

Abstract

Methamphetamine is a widely abused illicit drug. Recent epidemiological studies showed that methamphetamine increases the risk for developing Parkinson's disease (PD) in agreement with animal studies showing dopaminergic neurotoxicity. We examined the effect of repeated low and medium doses vs single high dose of methamphetamine on degeneration of dopaminergic terminals and cell bodies. Mice were given methamphetamine in one of the following paradigms: three injections of 5 or 10 mg/kg at 3 h intervals or a single 30 mg/kg injection. The integrity of dopaminergic fibers and cell bodies was assessed at different time points after methamphetamine by tyrosine hydroxylase immunohistochemistry and silver staining. The 3 × 10 protocol yielded the highest loss of striatal dopaminergic terminals, followed by the 3 × 5 and 1 × 30. Some degenerating axons could be followed from the striatum to the substantia nigra pars compacta (SNpc). All protocols induced similar significant degeneration of dopaminergic neurons in the SNpc, evidenced by amino-cupric-silver-stained dopaminergic neurons. These neurons died by necrosis and apoptosis. Methamphetamine also killed striatal neurons. By using D1-Tmt/D2-GFP BAC transgenic mice, we observed that degenerating striatal neurons were equally distributed between direct and indirect medium spiny neurons. Despite the reduced number of dopaminergic neurons in the SNpc at 30 days after treatment, there was a partial time-dependent recovery of dopamine terminals beginning 3 days after treatment. Locomotor activity and motor coordination were robustly decreased 1-3 days after treatment, but recovered at later times along with dopaminergic terminals. These data provide direct evidence that methamphetamine causes long-lasting loss/degeneration of dopaminergic cell bodies in the SNpc, along with destruction of dopaminergic terminals in the striatum.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24169803      PMCID: PMC3957101          DOI: 10.1038/npp.2013.307

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  61 in total

Review 1.  Axonal self-destruction and neurodegeneration.

Authors:  Martin C Raff; Alan V Whitmore; John T Finn
Journal:  Science       Date:  2002-05-03       Impact factor: 47.728

Review 2.  Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.

Authors:  David Sulzer
Journal:  Trends Neurosci       Date:  2007-04-05       Impact factor: 13.837

3.  Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; D Franceschi; M Sedler; S J Gatley; E Miller; R Hitzemann; Y S Ding; J Logan
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

4.  Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine.

Authors:  S Ares-Santos; N Granado; I Oliva; E O'Shea; E D Martin; M I Colado; R Moratalla
Journal:  Neurobiol Dis       Date:  2011-11-13       Impact factor: 5.996

5.  Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA.

Authors:  Noelia Granado; Sara Ares-Santos; Idaira Oliva; Esther O'Shea; Eduardo D Martin; M Isabel Colado; Rosario Moratalla
Journal:  Neurobiol Dis       Date:  2011-02-15       Impact factor: 5.996

6.  Brain region-specific neurodegenerative profiles showing the relative importance of amphetamine dose, hyperthermia, seizures, and the blood-brain barrier.

Authors:  John F Bowyer; Monzy Thomas; Larry C Schmued; Syed F Ali
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

7.  A study on the effect of JNK inhibitor, SP600125, on the disruption of blood-brain barrier induced by methamphetamine.

Authors:  Andres Urrutia; Ana Rubio-Araiz; Maria Dolores Gutierrez-Lopez; Ayman ElAli; Dirk M Hermann; Esther O'Shea; Maria Isabel Colado
Journal:  Neurobiol Dis       Date:  2012-10-12       Impact factor: 5.996

8.  Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers.

Authors:  G A Ricaurte; L S Seiden; C R Schuster
Journal:  Brain Res       Date:  1984-06-15       Impact factor: 3.252

Review 9.  Silver staining as a tool for neurotoxic assessment.

Authors:  C A Beltramino; J S de Olmos; F Gallyas; L Heimer; L Záborszky
Journal:  NIDA Res Monogr       Date:  1993

10.  Use of an amino-cupric-silver technique for the detection of early and semiacute neuronal degeneration caused by neurotoxicants, hypoxia, and physical trauma.

Authors:  J S de Olmos; C A Beltramino; S de Olmos de Lorenzo
Journal:  Neurotoxicol Teratol       Date:  1994 Nov-Dec       Impact factor: 3.763

View more
  55 in total

1.  Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors.

Authors:  Michelle G Baladi; Shannon M Nielsen; J Michael McIntosh; Glen R Hanson; Annette E Fleckenstein
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

2.  Neurotoxicity to dopamine neurons after the serial exposure to alcohol and methamphetamine: Protection by COX-2 antagonism.

Authors:  Amanda L Blaker; Eric A Rodriguez; Bryan K Yamamoto
Journal:  Brain Behav Immun       Date:  2019-06-20       Impact factor: 7.217

Review 3.  Role of Mitochondria in Methamphetamine-Induced Dopaminergic Neurotoxicity: Involvement in Oxidative Stress, Neuroinflammation, and Pro-apoptosis-A Review.

Authors:  Eun-Joo Shin; Hai-Quyen Tran; Phuong-Tram Nguyen; Ji Hoon Jeong; Seung-Yeol Nah; Choon-Gon Jang; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neurochem Res       Date:  2017-06-07       Impact factor: 3.996

Review 4.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

5.  Caspase-11 plays an essential role in methamphetamine-induced dopaminergic neuron apoptosis.

Authors:  Weiye Huang; Wei-Bing Xie; Dongfang Qiao; Pingming Qiu; Enping Huang; Bing Li; Chuanxiang Chen; Chao Liu; Qi Wang; Zhoumeng Lin; Huijun Wang
Journal:  Toxicol Sci       Date:  2015-01-27       Impact factor: 4.849

6.  Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling.

Authors:  Oscar Solís; Jose Ruben Garcia-Montes; Aldo González-Granillo; Ming Xu; Rosario Moratalla
Journal:  Cereb Cortex       Date:  2017-01-01       Impact factor: 5.357

Review 7.  Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.

Authors:  Stephen J Kish; Isabelle Boileau; Russell C Callaghan; Junchao Tong
Journal:  Eur J Neurosci       Date:  2016-09-05       Impact factor: 3.386

8.  Methamphetamine augment HIV-1 Tat mediated memory deficits by altering the expression of synaptic proteins and neurotrophic factors.

Authors:  Anantha Ram Nookala; Daniel C Schwartz; Nitish S Chaudhari; Alexy Glazyrin; Edward B Stephens; Nancy E J Berman; Anil Kumar
Journal:  Brain Behav Immun       Date:  2018-05-02       Impact factor: 7.217

9.  Methamphetamine-induced toxicity in indusium griseum of mice is associated with astro- and microgliosis.

Authors:  Ana Carmena; Noelia Granado; Sara Ares-Santos; Samuel Alberquilla; Yousef Tizabi; Rosario Moratalla
Journal:  Neurotox Res       Date:  2014-12-10       Impact factor: 3.911

10.  PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance.

Authors:  Emily E Reichard; Nisha Nanaware-Kharade; Guillermo A Gonzalez; Shraddha Thakkar; S Michael Owens; Eric C Peterson
Journal:  Pharm Res       Date:  2016-09-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.